Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Melchardt

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
ESMO Open|January 12, 2023
How I treat diffuse large B-cell lymphomaT Melchardt, A Egle, R Greil
Deutsche Medizinische Wochenschrift (1946)|October 3, 2013
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]T Melchardt, L Weiss, A Egle
Drugs of Today (Barcelona, Spain : 1998)|April 14, 2020
Ropeginterferon alfa-2b for the treatment of patients with polycythemia veraS M Wagner, T Melchardt, R Greil
The British Journal of Oral & Maxillofacial Surgery|November 11, 2017
Multiple myeloma of the mandibular condyle: a rare presentationG B Bottini, C Steiner, T Melchardt, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 16, 2014
R-CHOP versus R-COMP: are they really equally effective?M Mian, I Wasle, G Gamerith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2013
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphomaL Weiss, T Melchardt, S Habringer, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open|February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trialT Fuereder, K Klinghammer, D Hahn, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
ESMO Open|January 12, 2023
How I treat diffuse large B-cell lymphomaT Melchardt, A Egle, R Greil
Deutsche Medizinische Wochenschrift (1946)|October 3, 2013
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?]T Melchardt, L Weiss, A Egle
Drugs of Today (Barcelona, Spain : 1998)|April 14, 2020
Ropeginterferon alfa-2b for the treatment of patients with polycythemia veraS M Wagner, T Melchardt, R Greil
The British Journal of Oral & Maxillofacial Surgery|November 11, 2017
Multiple myeloma of the mandibular condyle: a rare presentationG B Bottini, C Steiner, T Melchardt, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 16, 2014
R-CHOP versus R-COMP: are they really equally effective?M Mian, I Wasle, G Gamerith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2013
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphomaL Weiss, T Melchardt, S Habringer, et al.
ESMO Open|August 9, 2021
Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literatureR Heregger, F Huemer, G Hutarew, et al.
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open|February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trialT Fuereder, K Klinghammer, D Hahn, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
Pageof 2